Cardinal Health (CAH)
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
$247.18-0.58%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
QuarterlyIQ Insights · CAH
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $247 CAH trades at 22× p/e, below its 23× p/e peer median. Our $330 fair value sits well above the price. We hold it with medium confidence: our number sits above the analyst range. Analysts target $250–$292. Note: our $330 fair value sits above the entire analyst range ($250–$292). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $274.50 | — | — | Analyst | high |
| dcf fcff | 12M | $1011.03 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $41.53 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $191.53 | 12.7 | 14.19 | TTM | high |
| Peer P/FCF |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$250.00 – $292.00 (median $274.50) · 10 analysts · as of 2026-08-19
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 67% over what the business is worth with no growth; closing that gap needs roughly 17.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $7.12/sh owner earnings.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2023-Q3, 2024-Q1, 2025-Q1, 2026-Q1
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $409.15 |
| 21.3 |
| 19.17 |
| TTM |
| high |
| Peer P/E | 12M | $240.39 | 18.7 | 12.82 | ntm analyst | high |
| PEG | 12M | $332.95 | 29.6 | 11.26 | TTM | high |
| Own P/E history | 12M | $248.34 | 22.1 | 11.26 | TTM | high |
| triangulated | 12M | $269.09 | 22.9 | 11.74 | Triangulated | high |
| Peer P/FCF | 3Y | $622.27 | 21.3 | 29.16 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $286.77 | 18.7 | 15.30 | Analyst | medium |
| PEG | 3Y | $452.35 | 29.6 | 15.30 | Analyst | medium |
| Own P/E history | 3Y | $337.39 | 22.1 | 15.30 | Analyst | medium |
| Peer P/FCF | 5Y | $822.95 | 21.3 | 38.57 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $326.99 | 18.7 | 17.44 | Analyst | high |
| PEG | 5Y | $515.79 | 29.6 | 17.44 | Analyst | high |
| Own P/E history | 5Y | $384.71 | 22.1 | 17.44 | Analyst | high |